Beigene Ltd
ONC353.920USD
+6.920+1.99%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
36.02B시가총액
575.45P/E TTM
자세한 내용은 Beigene Ltd 회사
BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Beigene Ltd 정보
종목 코드 ONC
회사 이름BeOne Medicines AG
상장일Mar 02, 2016
CEOOyler (John Victor)
직원 수11000
유형Depository Receipt
회계 연도 종료Mar 02
주소c/o BeOne Medicines I GmbH
도시BASEL
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가Switzerland
우편 번호4051
전화41616851900
웹사이트https://beonemedicines.com/
종목 코드 ONC
상장일Mar 02, 2016
CEOOyler (John Victor)
Beigene Ltd의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Dr. Eric E. Hedrick, M.D.
Dr. Eric E. Hedrick, M.D.
Interim Chief Medical Officer, Immuno-Oncology
Interim Chief Medical Officer, Immuno-Oncology
--
--
Mr. Anthony C. (Tony) Hooper
Mr. Anthony C. (Tony) Hooper
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Xiaobin Wu, Ph.D.
Dr. Xiaobin Wu, Ph.D.
President, Chief Operating Officer
President, Chief Operating Officer
10.89K
--
Mr. John Victor Oyler
Mr. John Victor Oyler
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
Co-Founder, Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ranjeev Krishana
Mr. Ranjeev Krishana
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Mr. Nuoqing (Michael) Yi
Mr. Nuoqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
기타
-1.31B
-92.66%
지역별USD
이름
수익
비율
United States
754.86M
53.45%
China
439.88M
31.15%
Europe
166.58M
11.79%
ROW
50.97M
3.61%
사업별
지역별
사업별USD
이름
수익
비율
Product
1.37B
97.35%
BRUKINSA
1.04B
73.69%
Tislelizumab
190.62M
13.50%
XGEVA
84.24M
5.97%
BLINCYTO
30.48M
2.16%
기타
-1.31B
-92.66%
주식 보유 통계
마지막 업데이트: Wed, Jan 14
마지막 업데이트: Wed, Jan 14
주주
주주 유형
주주
주주
비율
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
기타
62.04%
주주
주주
비율
Amgen Inc
17.27%
Baker Bros. Advisors LP
8.02%
PRIMECAP Management Company
4.63%
Capital International Investors
4.60%
Fidelity Management & Research Company LLC
3.43%
기타
62.04%
주주 유형
주주
비율
Investment Advisor
17.79%
Corporation
17.28%
Hedge Fund
8.20%
Investment Advisor/Hedge Fund
3.76%
Sovereign Wealth Fund
0.92%
Research Firm
0.57%
Pension Fund
0.05%
Family Office
0.02%
Family Office
0.02%
기타
51.38%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
581
34.32M
31.29%
-4.58M
2025Q3
565
40.04M
36.51%
-2.11M
2025Q2
558
63.29M
57.54%
+456.15K
2025Q1
585
69.06M
63.84%
+3.36M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Amgen Inc
18.94M
17.27%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.02%
--
--
Sep 30, 2025
PRIMECAP Management Company
5.08M
4.63%
-7.82K
-0.15%
Sep 30, 2025
Capital International Investors
5.05M
4.6%
+161.05K
+3.30%
Sep 30, 2025
Fidelity Management & Research Company LLC
3.76M
3.43%
+345.36K
+10.12%
Sep 30, 2025
HHLR Advisors, Ltd.
1.03M
0.94%
--
--
Sep 30, 2025
Temasek Holdings Pte. Ltd.
1.01M
0.92%
+999.00
+0.10%
Sep 30, 2025
T. Rowe Price International Ltd
941.86K
0.86%
+9.96K
+1.07%
Sep 30, 2025
T. Rowe Price Associates, Inc.
688.71K
0.63%
+600.48K
+680.59%
Sep 30, 2025
Invus Public Equities Advisors, LLC
492.99K
0.45%
-17.00K
-3.33%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
VanEck Biotech ETF
4.03%
First Trust NYSE Arca Biotechnology Index Fund
3.26%
Tema Oncology ETF
2.65%
Global X Aging Population ETF
2.41%
Virtus LifeSci Biotech Products ETF
1.8%
iShares Biotechnology ETF
1.71%
ProShares Ultra Nasdaq Biotechnology
1.02%
Invesco Nasdaq Biotechnology ETF
1.02%
National Security Emerging Markets Index ETF
0.83%
Capital Group Global Equity ETF
0.79%
더 보기
VanEck Biotech ETF
비율4.03%
First Trust NYSE Arca Biotechnology Index Fund
비율3.26%
Tema Oncology ETF
비율2.65%
Global X Aging Population ETF
비율2.41%
Virtus LifeSci Biotech Products ETF
비율1.8%
iShares Biotechnology ETF
비율1.71%
ProShares Ultra Nasdaq Biotechnology
비율1.02%
Invesco Nasdaq Biotechnology ETF
비율1.02%
National Security Emerging Markets Index ETF
비율0.83%
Capital Group Global Equity ETF
비율0.79%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
